Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis
- PMID: 23506540
- DOI: 10.3111/13696998.2013.787427
Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis
Abstract
Objective: To investigate adherence to dornase alfa therapy among commercially-insured patients with cystic fibrosis (CF) and to examine the impact of adherence on health and economic outcomes.
Methods: This retrospective cohort analysis included CF patients with ≥1 dornase alfa (Pulmozyme) pharmacy claim between 1 October 2006 and 30 September 2008 and with continuous enrollment in the health insurance plan at least 1 year before and 1 year after their index dornase alfa claim. Adherence was measured with the medication possession ratio (MPR). Multivariate models were used to estimate the relationship between adherence and exacerbations, utilization, and cost.
Results: Nine hundred and seven patients met the inclusion criteria. The mean age was 19.5 years (SD = 11.5) and 49.1% were female. Overall MPR was 0.59 and by age was 0.66 for patients of 5-12 years, 0.57 for 13-20 years, 0.54 for 21-30 years, and 0.56 for patients ≥31 years. Adherence was better in fall and winter than in spring and summer. There was no statistically significant difference in the proportion of patients with inpatient respiratory exacerbations across groups with low (<0.5), moderate (0.5-0.79), and high (≥0.8) adherence (24.5%, 22.3%, and 19.1%, respectively, p = 0.250). There was a trend toward higher total charges in more-adherent patients (mean $58,612 in the least-adherent group and mean $69,427 in the most adherent group, p = 0.107). In multivariate models, MPR was not significantly associated with the risk of inpatient respiratory exacerbations (hazard ratio = 1.16 for MPR <0.5 vs ≥0.8; 95% CI = 0.83-1.61).
Limitations: Study data were derived from insurance claims; adherence measures were based on prescription fills, not observed medication use.
Conclusion: Adherence to dornase alfa was generally low, but varied by age and season. Adherence was not found to be significantly associated with respiratory exacerbations or total charges, but was associated with shorter hospital length of stay.
Similar articles
-
Impact of pharmacy services on cystic fibrosis medication adherence.Pediatr Pulmonol. 2017 Aug;52(8):1006-1012. doi: 10.1002/ppul.23743. Epub 2017 Jun 13. Pediatr Pulmonol. 2017. PMID: 28608652
-
Adherence to treatment in children and adolescent patients with cystic fibrosis.J Adolesc Health. 2006 Jan;38(1):13-7. doi: 10.1016/j.jadohealth.2004.09.013. J Adolesc Health. 2006. PMID: 16387243
-
A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.J Pediatr. 2001 Dec;139(6):813-20. doi: 10.1067/mpd.2001.118570. J Pediatr. 2001. PMID: 11743506 Clinical Trial.
-
Dornase alfa (Pulmozyme).Curr Opin Pulm Med. 2012 Nov;18(6):609-14. doi: 10.1097/MCP.0b013e328358d51f. Curr Opin Pulm Med. 2012. PMID: 22990660 Review.
-
Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.Pharmacoeconomics. 1997 Sep;12(3):409-22. doi: 10.2165/00019053-199712030-00011. Pharmacoeconomics. 1997. PMID: 10170464 Review.
Cited by
-
Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data.Patient Prefer Adherence. 2019 Sep 4;13:1497-1510. doi: 10.2147/PPA.S211769. eCollection 2019. Patient Prefer Adherence. 2019. PMID: 31564837 Free PMC article.
-
Objective Measurement of Adherence to Out-Patient Airway Clearance Therapy by High-Frequency Chest Wall Compression in Cystic Fibrosis.Respir Care. 2017 Jul;62(7):920-927. doi: 10.4187/respcare.05349. Epub 2017 Apr 19. Respir Care. 2017. PMID: 28424226 Free PMC article.
-
Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives.Pediatr Pulmonol. 2015 Feb;50(2):127-36. doi: 10.1002/ppul.23017. Epub 2014 Mar 10. Pediatr Pulmonol. 2015. PMID: 24616259 Free PMC article.
-
A pragmatic behavior-based habit index for adherence to nebulized treatments among adults with cystic fibrosis.Patient Prefer Adherence. 2019 Feb 13;13:283-294. doi: 10.2147/PPA.S186417. eCollection 2019. Patient Prefer Adherence. 2019. PMID: 30863018 Free PMC article.
-
Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine.Genes (Basel). 2021 Apr 13;12(4):562. doi: 10.3390/genes12040562. Genes (Basel). 2021. PMID: 33924524 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous